Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-21
    E.g., 2018-10-21

Archive Search

Pages

15 results
12:00 AM, Jan 18, 2016  |  BioCentury | Strategy

Shire's serial story

2014. Shire has no cancer therapies in its pipeline. It does market one hematology drug: Xagrid
anagrelide for essential thrombocythemia, a rare blood disease associated with the increased production of blood platelets …
12:00 AM, Aug 10, 2015  |  BioCentury | Strategy

Shire's M&A stepping stone

a single cancer product on the market: Baxalta's recently acquired leukemia drug Oncaspar and Shire's Xagrid
anagrelide, which is marketed for essential thrombocytopenia. Both generate about $100 million in annual sales. Enyedy …
model." Of Baxalta's four late-stage cancer programs, three are for hematological malignancies. Enyedy added that Xagrid
12:00 AM, May 27, 2013  |  BioCentury | Strategy

Royalty pain or gain

disorders in Central Europe, the Commonwealth of Independent States (CIS) and the Middle East. AOP's anagrelide
12:00 AM, May 20, 2013  |  BioCentury | Strategy

R&D rewind

portfolio includes ADHD drug Adderall XR dextroamphetamine/amphetamine, hyperphosphatemia drug Fosrenol lanthanum carbonate and thrombocytopenia drug Xagrid
anagrelide. Companies and Institutions Mentioned Bayer AG (Xetra:BAYN), Leverkusen, Germany Bausch & Lomb Inc. , Rochester …
12:00 AM, Apr 02, 2012  |  BioCentury | Strategy

Shire's iron backbone

unit in areas that are specialty focused," he said. The company markets the hematology product Xagrid
anagrelide, a small molecule to reduce elevated platelet counts in at-risk essential thrombocythemia patients who are …
intolerant of or do not respond to hydroxyurea therapy. Xagrid had 2011 sales of $90.6 million …
12:00 AM, Aug 09, 2010  |  BioCentury | Strategy

Shire Early and Late

Intrathecal formulation of Elaprase idursulfase MPS-II (Hunter syndrome) with significant CNS symptoms Ph I/II SPD535 Anagrelide
12:00 AM, Jun 25, 2007  |  BioCentury | Strategy

Shire product sales

ADHD $863.6 Pentasa [Ferring] Ulcerative colitis (UC) $137.8 Replagal Fabry's disease $117.7 Carbatrol Epilepsy $68.3 Agrylin/Xagrid
12:00 AM, Feb 26, 2007  |  BioCentury | Strategy

Shire at the river’s edge

the 1999 purchase of Roberts Pharmaceutical Corp. for $1 billion in stock. The deal brought Agrylin
anagrelide to treat elevated platelets, Pentasa mesalamine to treat ulcerative colitis (UC) and ProAmatine midodrine to …
12:00 AM, Apr 25, 2005  |  BioCentury | Strategy

Stronger Context: The commercial imperative

sales: $607 million) through the takeover of Richwood Pharmaceutical Co. Inc. in 1997, and of Agrylin
anagrelide for thrombocythemia ($152.5 million) and Pentasa for ulcerative colitis ($115 million), obtained in the acquisition …
12:00 AM, Apr 25, 2005  |  BioCentury | Strategy

Shire-Transkaryotic pipeline

Indication Status (Milestones) Company Adderall & Adderall XR Attention deficit hyperactivity disorder (ADHD) Mkt SHP Agrylin
SHP/Ferring Proamatine/Amatine Symptomatic orthostatic hypotension Mkt SHP/Nycomed Reminyl Alzheimer's disease Mkt SHP/J&J (Janssen)/ Synaptech (A) Xagrid

Pages